Gossamer Bio Inc

GOSS03 Dec 2024
Healthcare
$0.73
+0.05 (+4.57%)
Lowest Today
$0.69
Highest Today
$0.73
Today’s Open
$0.73
Prev. Close
$0.7
52 Week High
$1.6
52 Week Low
$0.5
To Invest in Gossamer Bio Inc

Gossamer Bio Inc

Healthcare
GOSS03 Dec 2024
+0.05 (+4.57%)
1M
3M
6M
1Y
5Y
Low
$0.69
Day’s Range
High
$0.73
0.69
52 Week Low
$0.5
52-Week Range
52 Week High
$1.6
0.5
1 Day
-
1 Week
-0.99%
1 month return
-22.23%
3 month return
-20.15%
6 month return
+21.29%
1 Year return
-10.55%
3 Years return
-93.54%
5 Years return
-97.15%
10 Years return
-
Institutional Holdings
NEA Management Company, LLC
7.98
Artal Group S A
5.87
Vanguard Group Inc
5.19
Octagon Capital Advisors LP
4.05
ARCH VENTURE CORP
3.56
FMR Inc
3.5
Fidelity Select Biotechnology
3.49

Market Status

Fundamentals
Market Cap
159.01 mln
PB Ratio
2.94
PE Ratio
0
Enterprise Value
35.6 mln
Total Assets
311.92 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Organisation
Gossamer Bio Inc
Employees
135
Industry
Biotechnology
CEO
Mr. Faheem  Hasnain
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities